Pharmacokinetic changes of clozapine and norclozapine in a rat model of non-alcoholic fatty liver disease induced by orotic acid

References

• Baldessarini, R.J., et al., 1993. Tissue concentrations of clozapine and its metabolites in the rat. Neuropsychopharmacology: official Publication of the American College of Neuropsychopharmacology, 9 (2), 117–124.
   PubMed Web of Science ®Google Scholar
• Bang, W.S., et al., 2019. Effects of orotic acid-induced non-alcoholic fatty liver on the pharmacokinetics of metoprolol and its metabolites in rats. Journal of pharmacy & pharmaceutical sciences: a Publication of the Canadian Society for Pharmaceutical Sciences, Societe Canadienne Des Sciences Pharmaceutiques, 22 (1), 98–111.
   PubMed Web of Science ®Google Scholar
• Benet, L.Z., and Hoener, B.A., 2002. Changes in plasma protein binding have little clinical relevance. Clinical pharmacology and therapeutics, 71 (3), 115–121.
   PubMed Web of Science ®Google Scholar
• Bersani, F.S., et al., 2011. Factors affecting interindividual differences in clozapine response: a review and case report. Human psychopharmacology, 26 (3), 177–187.
   PubMed Web of Science ®Google Scholar
• Boulton, D. W., et al., 2002. In vitro P-glycoprotein affinity for atypical and conventional antipsychotics. Life Sciences, 71 (2), 163–169. 10.1016/S0024-3205(02)01680-6
   PubMed Web of Science ®Google Scholar
• Brzozowska, N.I., et al., 2017. The differential binding of antipsychotic drugs to the ABC transporter P-glycoprotein predicts cannabinoid-antipsychotic drug interactions. Neuropsychopharmacology : official Publication of the American College of Neuropsychopharmacology, 42 (11), 2222–2231.
   PubMed Web of Science ®Google Scholar
• Canet, M.J., et al., 2012. Altered arsenic disposition in experimental nonalcoholic fatty liver disease. Drug metabolism and disposition: the biological fate of chemicals, 40 (9), 1817–1824.
   PubMed Web of Science ®Google Scholar
• Chen, J.J., Chen, G.S., and Bunce, N.J., 2003. Inhibition of CYP 1A2-dependent MROD activity in rat liver microsomes: an explanation of the hepatic sequestration of a limited subset of halogenated aromatic hydrocarbons. Environmental toxicology, 18 (2), 115–119.
   PubMed Web of Science ®Google Scholar
• Cheng, Y.F., et al., 1988. Clinical pharmacokinetics of clozapine in chronic schizophrenic patients. European journal of clinical pharmacology, 34 (5), 445–449.
   PubMed Web of Science ®Google Scholar
• Chiou, W.L., 1978. Critical evaluation of the potential error in pharmacokinetic studies of using the linear trapezoidal rule method for the calculation of the area under the plasma level-time curve. Journal of pharmacokinetics and biopharmaceutics, 6 (6), 539–546.
   PubMedGoogle Scholar
• Consoli, G., et al., 2009. ABCB1 polymorphisms are associated with clozapine plasma levels in psychotic patients. Pharmacogenomics, 10 (8), 1267–1276.
   PubMed Web of Science ®Google Scholar
• Culot, M., et al., 2013. A simple method for assessing free brain/free plasma ratios using an in vitro model of the blood brain barrier. Plos one, 8 (12), e80634
   PubMed Web of Science ®Google Scholar
• Dain, J.G., Nicoletti, J., and Ballard, F., 1997. Biotransformation of clozapine in humans. Drug Metabolism and disposition: the biological fate of chemicals, 25 (5), 603–609.
   PubMed Web of Science ®Google Scholar
• Dickens, D., et al., 2018. Cellular uptake of the atypical antipsychotic clozapine is a carrier-mediated process. Molecular pharmaceutics, 15 (8), 3557–3572.
   PubMed Web of Science ®Google Scholar
• Duggleby, R.G., 1995. Analysis of enzyme progress curves by nonlinear regression. Methods in enzymology, 249, 61–90.
   PubMed Web of Science ®Google Scholar
• Farrell, G.C., Teoh, N.C., and McCuskey, R.S., 2008. Hepatic microcirculation in fatty liver disease. Anatomical record (Hoboken), 291 (6), 684–692.
   PubMedGoogle Scholar
• Fisher, C.D., et al., 2009a. Experimental non-alcoholic fatty liver disease results in decreased hepatic uptake transporter expression and function in rats. European journal of pharmacology, 613 (1-3), 119–127.
   PubMed Web of Science ®Google Scholar
• Fisher, C.D., et al., 2009b. Hepatic cytochrome P450 enzyme alterations in humans with progressive stages of nonalcoholic fatty liver disease. Drug metabolism and disposition: the biological fate of chemicals, 37 (10), 2087–2094.
   PubMed Web of Science ®Google Scholar
• Gershkovich, P., et al., 2010. Effect of hypertriglyceridemia on the pharmacokinetics and blood-brain barrier penetration of clozapine and norclozapine following administration to rats. European Neuropsychopharmacology: The Journal of the European College of Neuropsychopharmacology, 20 (8), 545–552.
   PubMed Web of Science ®Google Scholar
• Gibaldi M., Perrier, D., 1982. eds. Pharmacokinetics, 2nd ed. New York: Marcel–Dekker Inc.
   Google Scholar
• Hardwick, R.N., et al., 2012. Molecular mechanism of altered ezetimibe disposition in nonalcoholic steatohepatitis. Drug metabolism and disposition: the biological fate of chemicals, 40 (3), 450–460.
   PubMed Web of Science ®Google Scholar
• Ijaz, S., et al., 2003. Impairment of hepatic microcirculation in fatty liver. Microcirculation (New York, N.Y. : 1994), 10 (6), 447–456.
   PubMed Web of Science ®Google Scholar
• Jassim, G., et al., 2012. Acute effects of orexigenic antipsychotic drugs on lipid and carbohydrate metabolism in rat. Psychopharmacology, 219 (3), 783–794.
   PubMed Web of Science ®Google Scholar
• Jung, E.J., et al., 2011. Role of the AMPK/SREBP-1 pathway in the development of orotic acid-induced fatty liver. Journal of lipid research, 52 (9), 1617–1625.
   PubMed Web of Science ®Google Scholar
• Kuoppamäki, M., Syvälahti, E., and Hietala, J., 1993. Clozapine and N-desmethylclozapine are potent 5-HT1C receptor antagonists. European journal of pharmacology, 245 (2), 179–182.
   PubMed Web of Science ®Google Scholar
• Lee, J.H., and Lee, M.G., 2008. Telithromycin pharmacokinetics in rat model of diabetes mellitus induced by alloxan or streptozotocin. Pharmaceutical research, 25 (8), 1915–1924.
   PubMed Web of Science ®Google Scholar
• Lee, S.T., et al., 2012. Association study of 27 annotated genes for clozapine pharmacogenetics: validation of preexisting studies and identification of a new candidate gene, ABCB1, for treatment response. Journal of clinical psychopharmacology, 32 (4), 441–448.
   PubMed Web of Science ®Google Scholar
• Li, L.J., et al., 2012. Population pharmacokinetics of clozapine and its primary metabolite norclozapine in Chinese patients with schizophrenia. Acta pharmacologica sinica, 33 (11), 1409–1416.
   PubMed Web of Science ®Google Scholar
• Li, Y., et al., 2017. Artesunate prevents rats from the clozapine-induced hepatic steatosis and elevation in plasma triglycerides. Neuropsychiatric disease and treatment, 13, 2477–2487.
   PubMed Web of Science ®Google Scholar
• Lickteig, A.J., et al., 2007. Efflux transporter expression and acetaminophen metabolite excretion are altered in rodent models of nonalcoholic fatty liver disease. Drug metabolism and disposition: the biological fate of chemicals, 35 (10), 1970–1978.
   PubMed Web of Science ®Google Scholar
• Maggs, J.L., et al., 1995. The metabolic formation of reactive intermediates from clozapine, a drug associated with agranulocytosis in man. The journal of pharmacology and experimental therapeutics, 275 (3), 1463–1475.
   PubMed Web of Science ®Google Scholar
• Maines, L.W., et al., 2005. Evaluation of the role of P-glycoprotein in the uptake of paroxetine, clozapine, phenytoin and carbamazapine by bovine retinal endothelial cells. Neuropharmacology, 49 (5), 610–617.
   PubMed Web of Science ®Google Scholar
• Manvich, D.F., et al., 2018. The DREADD agonist clozapine N-oxide (CNO) is reverse-metabolized to clozapine and produces clozapine-like interoceptive stimulus effects in rats and mice. Scientific reports, 8 (1), 3840.
   PubMed Web of Science ®Google Scholar
• Mendoza, M.C., and Lindenmayer, J.P., 2009. N-desmethylclozapine: is there evidence for its antipsychotic potential? Clinical neuropharmacology, 32 (3), 154–157.
   PubMed Web of Science ®Google Scholar
• Ozdemir, V., et al., 2001. Treatment-resistance to clozapine in association with ultrarapid CYP1A2 activity and the C–>A polymorphism in intron 1 of the CYP1A2 gene: effect of grapefruit juice and low-dose fluvoxamine. Journal of clinical psychopharmacology, 21, 603–607.
   PubMed Web of Science ®Google Scholar
• Pacher, P., and Kecskemeti, V., 2004. Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns? Current pharmaceutical design, 10 (20), 2463–2475.
   PubMed Web of Science ®Google Scholar
• Piatkov, I., et al., 2017. ABCB1 and ABCC1 single-nucleotide polymorphisms in patients treated with clozapine. Pharmacogenomics and personalized medicine, 10, 235–242.
   PubMed Web of Science ®Google Scholar
• Pirmohamed, M., et al., 1995. Metabolism and bioactivation of clozapine by human liver in vitro. The journal of pharmacology and experimental therapeutics, 272 (3), 984–990.
   PubMed Web of Science ®Google Scholar
• Raper, J., et al., 2017. Metabolism and distribution of clozapine-N-oxide: implications for nonhuman primate chemogenetics. ACS chemical neuroscience, 8 (7), 1570–1576.
   PubMed Web of Science ®Google Scholar
• Schmitt, U., et al., 2012. In vitro p-glycoprotein efflux inhibition by atypical antipsychotics is in vivo nicely reflected by pharmacodynamic but less by pharmacokinetic changes. Pharmacology, biochemistry, and behavior, 102 (2), 312–320.
   PubMed Web of Science ®Google Scholar
• Su, G.M., Sefton, R.M., and Murray, M., 1999. Down-regulation of rat hepatic microsomal cytochromes P-450 in microvesicular steatosis induced by orotic acid. The journal of pharmacology and experimental therapeutics, 291 (3), 953–959.
   PubMed Web of Science ®Google Scholar
• Summerfield, S.G., and Dong, K.C., 2013. In vitro, in vivo and in silico models of drug distribution into the brain. Journal of pharmacokinetics and pharmacodynamics, 40 (3), 301–314.
   PubMed Web of Science ®Google Scholar
• Summerfield, S.G., Zhang, Y., and Liu, H., 2016. Examining the uptake of central nervous system drugs and candidates across the blood-brain barrier. The journal of pharmacology and experimental therapeutics, 358 (2), 294–305.
   PubMed Web of Science ®Google Scholar
• Sun, L., and Lau, C.E., 2000. Intravenous and oral clozapine pharmacokinetics, pharmacodynamics, and concentration-effect relations: acute tolerance. European journal of pharmacology, 398 (2), 225–238.
   PubMed Web of Science ®Google Scholar
• Wang, W., et al., 2019. Clozapine-induced reduction of l-carnitine reabsorption via inhibition/down-regulation of renal carnitine/organic cation transporter 2 contributes to liver lipid metabolic disorder in mice. Toxicology and applied pharmacology, 363, 47–56.
   PubMed Web of Science ®Google Scholar
• Wang, Y.M., et al., 2011. Study on possible mechanism of orotic acid-induced fatty liver in rats. Nutrition (Burbank, Los Angeles County, Calif.), 27 (5), 571–575.
   PubMed Web of Science ®Google Scholar
• Weigmann, H., et al., 1999. Distribution of clozapine and desmethylclozapine between blood and brain in rats. European neuropsychopharmacology:the journal of the European College of Neuropsychopharmacology, 9 (3), 253–256.
   PubMed Web of Science ®Google Scholar
• Wilkinson, G.R., and Shand, D.G., 1975. Commentary: a physiological approach to hepatic drug clearance. Clinical pharmacology and therapeutics, 18 (4), 377–390.
   PubMed Web of Science ®Google Scholar
• Yun, K.U., et al., 2010. Age-related changes in hepatic expression and activity of cytochrome P450 in male rats. Archives of toxicology, 84 (12), 939–946.
   PubMed Web of Science ®Google Scholar
• Zhang, W.V., Ramzan, I., and Murray, M., 2007. Impaired microsomal oxidation of the atypical antipsychotic agent clozapine in hepatic steatosis. The journal of pharmacology and experimental therapeutics, 322 (2), 770–777.
   PubMed Web of Science ®Google Scholar